ADC Therapeutics to Present at the BofA Securities 2022 Healthcare Conference

ADC Therapeutics to Present at the BofA Securities

2022 Healthcare Conference

LAUSANNE, Switzerland,

May 4, 2022 - ADC Therapeutics SA (NYSE: ADCT), a commercial-stage biotechnology company improving the lives of those affected

by cancer with its next-generation, targeted antibody drug conjugates (ADCs) for patients with hematologic malignancies and solid tumors,

announced today that its executives will be participating in a fireside chat at the BofA Securities 2022 Healthcare Conference on Tuesday,

May 10, 2022, at 1:40 pm ET.

the presentation will be available via the Events & Presentations page in the Investors section of ADC Therapeutics' website,

ir.adctherapeutics.com. A replay of the webcast will be available for approximately 30 days.

About ADC Therapeutics

(NYSE: ADCT) is a commercial-stage biotechnology company improving the lives of those affected by cancer with its next-generation, targeted

antibody drug conjugates (ADCs). The Company is advancing its proprietary PBD-based ADC technology to transform the treatment paradigm

for patients with hematologic malignancies and solid tumors.

CD19-directed ADC ZYNLONTA (loncastuximab tesirine-lpyl) is approved by the FDA for the treatment of relapsed or refractory diffuse large

b-cell lymphoma after two or more lines of systemic therapy. ZYNLONTA is also in development in combination with other agents. Cami (camidanlumab

tesirine) is being evaluated in a pivotal Phase 2 trial for relapsed or refractory Hodgkin lymphoma and in a Phase 1b clinical trial

for various advanced solid tumors. In addition to ZYNLONTA and Cami, ADC Therapeutics has multiple ADCs in ongoing clinical and preclinical

is based in Lausanne (Biop le), Switzerland and has operations in London, the San Francisco Bay Area and New Jersey. For more information,

please visit https://adctherapeutics.com/ and follow the Company on Twitter and LinkedIn.

ZYNLONTA is a registered trademark

of ADC Therapeutics SA.

Tel.: +44 7879 627205

Tel.: +1 917 288 7023

Tel: +41 (0) 43 268 3231

Tel.: +1 914-552-4625